Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$2.50 +2.5%	$1.98	$0.80 ▼ $3.42	$102.71M	-0.88	1.18 million shs	84,243 shs
ANL Adlai Nortye	$1.69 -3.4%	$1.55	$1.10 ▼ $3.89	$62.36M	-0.95	5,579 shs	57,939 shs
GPH Graphite One	C$1.02 +4.1%	C$0.84	C$0.64 ▼ C$1.14	C$103.28M	1.02	90,433 shs	180,264 shs
HURA TuHURA Biosciences	$3.06 +10.9%	$2.58	$1.80 ▼ $8.63	$133.66M	0.04	763,765 shs	643,125 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	0.00%	+3.73%	+52.44%	+145.10%	+29.87%
ANL Adlai Nortye	0.00%	+7.30%	+12.67%	-15.08%	-48.79%
GPH Graphite One	0.00%	0.00%	+20.00%	+29.11%	+25.93%
HURA TuHURA Biosciences	0.00%	+33.04%	+20.95%	-21.94%	+305,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.2497 of 5 stars	3.3	3.0	0.0	0.0	2.7	1.7	0.0
ANL Adlai Nortye	1.3521 of 5 stars	3.0	3.0	0.0	0.0	1.8	0.0	0.0
GPH Graphite One	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	1.8022 of 5 stars	3.7	0.0	0.0	0.0	2.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	2.50	Moderate Buy	$5.50	120.00% Upside
ANL Adlai Nortye	2.00	Hold	$9.00	432.54% Upside
GPH Graphite One	0.00	N/A	N/A	N/A
HURA TuHURA Biosciences	3.40	Buy	$12.67	313.94% Upside

Current Analyst Ratings Breakdown

Latest ANL, HURA, GPH, and ANEB Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/23/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/2/2025	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	$0.69 per share	N/A
GPH Graphite One	N/A	N/A	C$0.01 per share	94.17	C$0.44 per share	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	9/24/2025 (Estimated)
ANL Adlai Nortye	-$51.87M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
GPH Graphite One	-C$4.90M	-C$0.07	N/A	∞	N/A	N/A	-10.96%	-6.61%	N/A
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	291.69%	122.09%	10/6/2025 (Estimated)

Latest ANL, HURA, GPH, and ANEB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	HURA TuHURA Biosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
GPH Graphite One	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
ANL Adlai Nortye	0.02	1.41	1.41
GPH Graphite One	0.02	1.09	0.33
HURA TuHURA Biosciences	N/A	3.00	3.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
ANL Adlai Nortye	35.21%
GPH Graphite One	0.07%
HURA TuHURA Biosciences	0.62%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
ANL Adlai Nortye	N/A
GPH Graphite One	28.81%
HURA TuHURA Biosciences	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.09 million	7.97 million	Not Optionable
ANL Adlai Nortye	127	36.90 million	N/A	Not Optionable
GPH Graphite One	20	101.25 million	N/A	Not Optionable
HURA TuHURA Biosciences	N/A	43.68 million	43.59 million	N/A

ANL, HURA, GPH, and ANEB Headlines

Recent News About These Companies

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

August 14 at 4:15 PM | prnewswire.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Buy" from Brokerages

August 14 at 2:27 AM | marketbeat.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Buy" from Brokerages

August 13, 2025 | americanbankingnews.com

TuHURA Biosciences files to sell 4.76M shares of common stock for holders

August 12, 2025 | msn.com

TuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stake

August 12, 2025 | finance.yahoo.com

TuHURA Biosciences (NASDAQ:HURA) Stock Acquired Rep. Laurel M. Lee

August 12, 2025 | marketbeat.com

TuHURA Biosciences (NASDAQ:HURA) Upgraded by Wall Street Zen to "Hold" Rating

July 19, 2025 | marketbeat.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Buy" from Brokerages

July 19, 2025 | marketbeat.com

TuHURA Biosciences, Inc. Common Stock (HURA) Insider Activity

July 14, 2025 | nasdaq.com

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Seeking Alpha

July 3, 2025 | seekingalpha.com

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Morningstar

July 3, 2025 | morningstar.comM

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

July 1, 2025 | finance.yahoo.com

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000Â® and Russell 2000Â® Indexes

July 1, 2025 | prnewswire.com

TuHURA Biosciences, Inc.: TuHURA Biosciences Completes Acquisition of Kineta

June 30, 2025 | finanznachrichten.de

TuHURA Biosciences Completes Acquisition of Kineta

June 30, 2025 | prnewswire.com

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals - Morningstar

June 25, 2025 | morningstar.comM

TuHURA initiates phase 3 trial for cancer immunotherapy drug

June 25, 2025 | uk.investing.com

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or ...

June 25, 2025 | morningstar.comM

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

June 24, 2025 | prnewswire.com

Tuhura Biosciences Surges After-Hours As Investors Bet On Kineta Merger, Cancer Drug Pipeline

June 23, 2025 | msn.com

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

June 23, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANL, HURA, GPH, and ANEB Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.50 +0.06 (+2.46%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.52 +0.02 (+1.00%)

As of 08/15/2025 04:10 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Adlai Nortye NASDAQ:ANL

$1.69 -0.06 (-3.43%)

Closing price 08/15/2025 03:56 PM Eastern

Extended Trading

$1.74 +0.05 (+2.66%)

As of 08/15/2025 05:41 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Graphite One CVE:GPH

C$1.02 +0.04 (+4.08%)

As of 08/15/2025 03:59 PM Eastern

Graphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

TuHURA Biosciences NASDAQ:HURA

$3.06 +0.30 (+10.87%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.00 -0.06 (-2.12%)

As of 08/15/2025 07:59 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time